Home
/
Inhibrx Biosciences, Inc.
/
Financials
/
Quarterly
Inhibrx Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Inhibrx Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 14, 2025
Q2
2025
Jun 30, 2025
$1.30M
Aug 13, 2025
Q1
2025
Mar 31, 2025
$0
May 14, 2025
Q3
2025
Sep 30, 2024
$0
Nov 14, 2025
Q2
2025
Jun 30, 2024
$100.0K
Aug 13, 2025
Q1
2025
Mar 31, 2024
$0
May 14, 2025
Q3
2024
Sep 30, 2023
$119.0K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$30.0K
Aug 13, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($35.26M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($28.65M)
Aug 13, 2025
Q3
2025
Jun 30, 2025
($28.65M)
Nov 14, 2025
Q1
2025
Mar 31, 2025
($43.31M)
May 14, 2025
Q2
2025
Mar 31, 2025
($43.31M)
Aug 13, 2025
Q3
2025
Mar 31, 2025
($43.31M)
Nov 14, 2025
Q3
2025
Sep 30, 2024
($43.86M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
$1.86B
Aug 13, 2025
Q3
2025
Jun 30, 2024
$1.86B
Nov 14, 2025
Q1
2025
Mar 31, 2024
($78.71M)
May 14, 2025
Q2
2025
Mar 31, 2024
($78.71M)
Aug 13, 2025
Q3
2025
Mar 31, 2024
($78.71M)
Nov 14, 2025
Q3
2024
Sep 30, 2023
($51.79M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($47.05M)
Aug 13, 2024
Q3
2024
Jun 30, 2023
($47.05M)
Nov 14, 2024
Q2
2024
Mar 31, 2023
($48.92M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($48.92M)
Nov 14, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($33.81M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($27.39M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($42.90M)
May 14, 2025
Q3
2025
Sep 30, 2024
($46.80M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($160.90M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($73.83M)
May 14, 2025
Q3
2024
Sep 30, 2023
($45.83M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($41.34M)
Aug 13, 2024